OBJECTIVE: Estimation of glomerular filtration rate (eGFR) is essential in the diagnosis and monitoring of patients with kidney disease and for correct dosage of drugs eliminated from the circulation by the kidneys. Cystatin C has been shown in several studies to be superior to creatinine in estimating eGFR. However, there are few studies on the performance of cystatin C estimated eGFR (eGFRCystC) in patients with advanced kidney disease and low GFR. MATERIAL AND METHODS: We measured serum cystatin C, together with serum creatinine, during iohexol clearance in patients with iohexol clearance below 30 mL/min/1.73 m2. The cystatin C values were used to calculate eGFRCystC using the formula eGFR (mL/min/1.73 m2) = 79.901*(cystatin C value in mg/L)-1.4389. RESULTS: There was good correlation between eGFRCystC and iohexol clearance (r = 0.88) in patients with iohexol clearance <30 mL/min/1.73 m2 and none of the patients had a difference between eGFRCystC and iohexol clearance exceeding 50 %. The Modification of Diet in Renal Disease (MDRD) equation and corrected MDRD eGFR showed a positive bias and weaker correlations with iohexol eGFR (MDRD = 5.32+1.22*iohexol clearance; corrected MDRD = 4.76+1.10*iohexol clearance; r = 0.59). For MDRD eGFR, 42 of 94 (44.7%) samples showed more than 50% difference to iohexol clearance. CONCLUSIONS: eGFRCystC is an efficient, practical and cost-effective alternative to iohexol clearance in patients with reduced GFR.
OBJECTIVE: Estimation of glomerular filtration rate (eGFR) is essential in the diagnosis and monitoring of patients with kidney disease and for correct dosage of drugs eliminated from the circulation by the kidneys. Cystatin C has been shown in several studies to be superior to creatinine in estimating eGFR. However, there are few studies on the performance of cystatin C estimated eGFR (eGFRCystC) in patients with advanced kidney disease and low GFR. MATERIAL AND METHODS: We measured serum cystatin C, together with serum creatinine, during iohexol clearance in patients with iohexol clearance below 30 mL/min/1.73 m2. The cystatin C values were used to calculate eGFRCystC using the formula eGFR (mL/min/1.73 m2) = 79.901*(cystatin C value in mg/L)-1.4389. RESULTS: There was good correlation between eGFRCystC and iohexol clearance (r = 0.88) in patients with iohexol clearance <30 mL/min/1.73 m2 and none of the patients had a difference between eGFRCystC and iohexol clearance exceeding 50 %. The Modification of Diet in Renal Disease (MDRD) equation and corrected MDRD eGFR showed a positive bias and weaker correlations with iohexol eGFR (MDRD = 5.32+1.22*iohexol clearance; corrected MDRD = 4.76+1.10*iohexol clearance; r = 0.59). For MDRD eGFR, 42 of 94 (44.7%) samples showed more than 50% difference to iohexol clearance. CONCLUSIONS:eGFRCystC is an efficient, practical and cost-effective alternative to iohexol clearance in patients with reduced GFR.
Authors: Amanda Hyre Anderson; Wei Yang; Chi-yuan Hsu; Marshall M Joffe; Mary B Leonard; Dawei Xie; Jing Chen; Tom Greene; Bernard G Jaar; Patricia Kao; John W Kusek; J Richard Landis; James P Lash; Raymond R Townsend; Matthew R Weir; Harold I Feldman Journal: Am J Kidney Dis Date: 2012-06-02 Impact factor: 8.860
Authors: Almudena Vega; Soledad García de Vinuesa; Marian Goicoechea; Ursula Verdalles; María Luz Martínez-Pueyo; Ana Chacón; Borja Quiroga; José Luño Journal: Int Urol Nephrol Date: 2013-11-22 Impact factor: 2.370
Authors: Fariborz Mobarrez; Anna Vikerfors; Johanna T Gustafsson; Iva Gunnarsson; Agneta Zickert; Anders Larsson; David S Pisetsky; Håkan Wallén; Elisabet Svenungsson Journal: Sci Rep Date: 2016-10-25 Impact factor: 4.379